Published: 07/1/2026 | Author: Eric Owens

A veterinary sedative powerful enough to immobilize a rhinoceros has moved into the U.S. fentanyl supply, and federal health agencies say it makes overdoses harder to reverse. On April 2, 2026, the CDC and the White House Office of National Drug Control Policy issued a joint health advisory warning that medetomidine has rapidly displaced xylazine as the dominant sedative mixed into illicit fentanyl.

For individuals who use opioids and the families who love them, the change carries a hard message. Harm reduction still works, but it can’t reverse everything now found in the fentanyl supply, including mixed polysubstances.

A More Potent Successor to Xylazine

Medetomidine, known on the street as rhino tranq, belongs to the same drug class as xylazine, the sedative that became known as tranq dope. But it’s far stronger. The advisory describes medetomidine as up to 100-200x more powerful than xylazine. Tranq produces deep sedation, a dangerously slowed heart rate, and very low blood pressure that can last for hours after the fentanyl wears off.

Naloxone, sold as Narcan, reverses opioid overdoses by knocking opioids off their receptors in the brain. Medetomidine works on a different system, so naloxone has no effect on it. First responders are finding people who stay deeply unconscious even after several doses of naloxone have restored their breathing.

The CDC still urges anyone responding to a suspected overdose to give naloxone right away for the opioid. Then, call 911 because the person may need breathing and heart support for an extended period.

The Numbers Behind the Surge

The shift has been fast. Medetomidine detections rose from 247 cases in 2023 to 8,233 in 2025, an increase of more than 3,000% in two years. The drug has turned up in at least 18 states, with the highest concentrations in the Northeastern areas like New York and the Midwest. At eight sentinel drug-testing sites, tranq appeared in more than half of opioid-positive samples, while xylazine detections have begun to fall.

The risk doesn’t end with the overdose. People who use medetomidine regularly can develop a severe withdrawal that resembles clonidine withdrawal, with sharp spikes in blood pressure, intense anxiety, nausea and fluctuating consciousness that may require emergency care. Dr. Colleen Huzinec, a clinical pharmacist who specializes in toxicology, reported how “the sedation is deeper, the cardiovascular effects are more severe.”

Harm Reduction & Treatment

Fentanyl remains dangerous; it’s still the primary cause of overdose deaths, so carrying and using naloxone is still essential. Harm reduction groups note that xylazine test strips can offer false reassurance by detecting a declining threat while missing the rising one. 

These developments come as national overdose deaths have fallen 50% since 2023. But public health officials say this trend remains fragile. New addictions like tranq threaten to undo that progress.

If you or someone you know is living with opioid use disorder, support is available through Narcotics Anonymous meetings, medication-assisted treatment such as methadone or buprenorphine, and local harm reduction services that distribute naloxone.

Starting with NA

Prolonged unconsciousness despite normal breathing may signal a sedative like medetomidine. For those who do take drugs, avoid using alone whenever possible.

Starting recovery is never easy. But help exists, right in your own neighborhood. By enrolling in a local Narcotics Anonymous chapter, you can meet peers who understand your experience and empathize with you. This lifelong fellowship sustains recovery and remains confidential and free.

To find NA meetings and opioid treatment options near you, call 800-934-1582(Sponsored) . You can also browse our directory for NA chapters across the nation.